Johnson & Johnson snaps six days of losing streak
by
Contributor since / Followers
Contributor since / Followers
10 hours ago
Johnson & Johnson (NYSE:JNJ) shares traded in the green on Monday, snapping six consecutive days
JNJ
Johnson & Johnson Is A Better Dividend Stock Than Amgen In Our View
by Sensor Unlimited
Contributor since 2021 / 8931 Followers
Contributor since 2021 / 8931 Followers
4 days ago
Summary: Recent market concerns have pressured the stock prices of both Johnson & Johnson and
Johnson & Johnson seeks approval of pediatric indications for TREMFYA
by
Contributor since / Followers
Contributor since / Followers
1 week ago
Sundry Photography/iStock Editorial via Getty Images Johnson & Johnson (NYSE:JNJ) submitted two supplemental Biologics License
How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding
by Frederik Mueller
Contributor since 2022 / 8528 Followers
Contributor since 2022 / 8528 Followers
2 weeks ago
Summary: Johnson & Johnson offers investors an effective combination of dividend income and dividend growth,
AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe
by
Contributor since / Followers
Contributor since / Followers
2 weeks ago
Roland Magnusson/iStock Editorial via Getty Images AstraZeneca’s (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese
Sanofi becomes latest drugmaker to challenge HHS over 340B drug-discount program
by
Contributor since / Followers
Contributor since / Followers
3 weeks ago
HJBC Following in the footsteps of Johnson & Johnson (JNJ) and Eli Lilly (LLY), Sanofi
Johnson & Johnson seeks FDA approval for its ulcerative colitis treatment
by
Contributor since / Followers
Contributor since / Followers
3 weeks ago
J Studios Johnson & Johnson (NYSE:JNJ) announced submission of a supplemental Biologics License Application to
Dividend Roundup: General Mills, Halliburton, Johnson & Johnson, Coca-Cola, and others
by
Contributor since / Followers
Contributor since / Followers
3 weeks ago
PM Images This week’s dividend activity included increased payouts from Merck (MRK) and McCormick (MKC)
Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive
by Mike Zaccardi, CFA, CMT
Contributor since 2022 / 6986 Followers
Contributor since 2022 / 6986 Followers
3 weeks ago
Summary: The Health Care sector faces uncertainty due to speculation about Robert F. Kennedy, Jr.
J&J unveils positive phase 3 results for icotrokinra for plaque psoriasis
by
Contributor since / Followers
Contributor since / Followers
3 weeks ago
tumeyes/iStock via Getty Images A phase 3 trial of Johnson & Johnson’s (NYSE:JNJ) icotrokinra for